Ozempic Novo Nordisk Pharmaceuticals Pty Ltd
Product name
Ozempic
Accepted date
Sep-2024
Active ingredients
Semaglutide
Proposed indication
To reduce the risk of kidney failure.
Application type
C (new indication)
Publication date
Sep-2024